Europe & Central Asia (IDA & IBRD countries) vs Palau: Immunization, Hib3
Immunization, Hib3 over time
- Europe & Central Asia (IDA & IBRD countries)
- Palau
How they compare
Palau currently reports 99.0% against 93.4% in Europe & Central Asia (IDA & IBRD countries), a difference of 5.6%.
That makes Palau's figure about 1.1 times Europe & Central Asia (IDA & IBRD countries)'s.
The two have swapped places 4 times across 27 shared years of data; in 1998 it was Palau ahead.
Europe & Central Asia (IDA & IBRD countries) ranks 3rd and Palau ranks 1st of 43 groups.
Palau has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Europe & Central Asia (IDA & IBRD countries) | Palau | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 85.0% | 85.0% | Palau |
| 2000s | 13.2% | 90.2% | 77.0% | Palau |
| 2010s | 64.0% | 90.5% | 26.5% | Palau |
| 2020s | 83.7% | 91.0% | 7.3% | Palau |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Europe & Central Asia (IDA & IBRD countries) or Palau?
- Palau, at 99.0% against 93.4% in Europe & Central Asia (IDA & IBRD countries) as of 2024.
- What is the difference in immunization, hib3 between Europe & Central Asia (IDA & IBRD countries) and Palau?
- 5.6%, with Palau ahead.
- How many years of comparable data are there for Europe & Central Asia (IDA & IBRD countries) and Palau?
- 27 years are reported by both, from 1998 to 2024.
- How do Europe & Central Asia (IDA & IBRD countries) and Palau rank globally for immunization, hib3?
- Europe & Central Asia (IDA & IBRD countries) ranks 3rd and Palau ranks 1st of 43 groups.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.